NVIDIA And 2 Other Stocks That May Be Considered Undervalued

The United States market has experienced a significant fluctuation recently, dropping by 13% in the last week yet showing a 13% increase over the past year. In such volatile conditions, identifying stocks that are potentially undervalued can be crucial for investors seeking opportunities, especially when earnings are forecast to grow by 18% annually.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name	Current Price	Fair Value (Est)	Discount (Est)
UiPath (PATH)	$12.19	$23.78	48.7%
SouthState Bank (SSB)	$101.69	$191.70	47%
Provident Financial Services (PFS)	$22.53	$43.03	47.6%
Orrstown Financial Services (ORRF)	$41.48	$76.13	45.5%
Northrim BanCorp (NRIM)	$24.52	$46.85	47.7%
Northeast Bank (NBN)	$126.26	$247.25	48.9%
Futu Holdings (FUTU)	$112.27	$208.52	46.2%
Civista Bancshares (CIVB)	$26.71	$53.11	49.7%
Chagee Holdings (CHA)	$11.45	$22.48	49.1%
Capital Bancorp (CBNK)	$36.12	$66.26	45.5%

Click here to see the full list of 44 stocks from our Undervalued US Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

NVIDIA (NVDA)

Overview: NVIDIA Corporation operates as a data center scale AI infrastructure company with a market cap of $5.43 trillion, serving the United States, Taiwan, China, Hong Kong, Europe, and other international markets.

Operations: The company's revenue is derived from two main segments: Graphics, generating $27.56 billion, and Compute & Networking, contributing $275.41 billion.

Estimated Discount To Fair Value: 24.4%

NVIDIA, trading at US$228.86, appears undervalued based on discounted cash flow analysis with a fair value estimate of US$302.83. The stock trades over 20% below this future cash flow valuation, indicating potential relative value compared to peers and industry standards. Despite significant insider selling recently, NVIDIA's earnings are forecasted to grow significantly at 26.68% annually over the next three years, outpacing the broader U.S. market growth rate of 17.6%.

• According our earnings growth report, there's an indication that NVIDIA might be ready to expand.
• Delve into the full analysis health report here for a deeper understanding of NVIDIA.

Insulet (PODD)

Overview: Insulet Corporation develops, manufactures, and sells insulin delivery systems for individuals with insulin-dependent diabetes both in the United States and internationally, with a market cap of approximately $9.44 billion.

Operations: The company's revenue segment is focused on drug delivery systems, generating approximately $3.05 billion.

Estimated Discount To Fair Value: 44.9%

Insulet, trading at US$133.11, is significantly undervalued based on its future cash flow value of US$241.73, offering potential value relative to peers and industry standards. Despite a forecasted earnings growth of 16.66% annually—slightly below the U.S. market average—the company recently refinanced US$475 million in term loans at lower interest rates and expanded its revolving credit facility by US$250 million, enhancing financial flexibility amidst ongoing product recalls and legal challenges.

• The analysis detailed in our Insulet growth report hints at robust future financial performance.
• Dive into the specifics of Insulet here with our thorough financial health report.

AngloGold Ashanti (AU)

Overview: AngloGold Ashanti plc is a gold mining company with operations in Africa, Australia, and the Americas, and has a market cap of $50.55 billion.

Operations: The company's revenue is primarily derived from its Metals & Mining segment, specifically in Gold & Other Precious Metals, amounting to $11.83 billion.

Estimated Discount To Fair Value: 23.1%

AngloGold Ashanti, trading at US$92.77, is undervalued based on its future cash flow value of US$120.58, presenting a good relative value compared to peers and industry standards. Despite slower revenue growth forecasts of 0.3% annually, earnings are expected to grow by 8.83% per year. Recent net income rose significantly to US$2.28 billion for the half-year ended June 30, 2026, alongside a planned share repurchase program worth up to US$2 billion pending shareholder approval.

• Upon reviewing our latest growth report, AngloGold Ashanti's projected financial performance appears quite optimistic.
• Click here to discover the nuances of AngloGold Ashanti with our detailed financial health report.

Next Steps

• Gain an insight into the universe of 44 Undervalued US Stocks Based On Cash Flows by clicking here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com